The approval late last month of Bavencio, a treatment for an unusual and aggressive form of skin cancer, relied on two Food and Drug Administration programs designed to expedite drug review and usher them to the market faster.
Medication for a potentially lethal hereditary disease will undergo an accelerated FDA approval process likely to bring it quickly to market, according to a recent announcement from manufacturer Shire Plc.
An early round of clinical testing shows that users of Opdivo, a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.
Zejula, an anti-cancer drug that inhibits the ability of tumor cells to self-repair, has been approved by the Food and Drug Administration (FDA) for sale in the United States after a clinical trial showed the drug works on a broader range of cancers.
A drug approved two years ago in the United States to treat schizophrenia is undergoing review in Europe, the final step before doctors there can prescribe it some 5 million patients suffering from the disorder.
Advocating the role of big data in improving patient outcomes, Sharon B. Arnold, acting director of the Agency for Healthcare Research & Quality, recently outlined the case for expanding its use in medicine.
The Agency for Healthcare Research & Quality (AHRQ) will conduct a study to use additional technology in hospitals, with the overall goal of augmenting safety and preventing costly surgical complications.